Latest news with #cancervaccine
Medscape
3 days ago
- Health
- Medscape
NHS to Fast-Track Patients into mRNA Cancer Vaccine Trial
Patients in England with advanced head and neck cancers will be fast-tracked into a trial of a new cancer vaccine using mRNA technology. The investigational vaccine is designed to help the immune system recognise and destroy cancer cells containing human papillomavirus (HPV) proteins. NHS England said more than 100 patients will be matched to the trial over the next year at 15 NHS hospitals. Third Trial via Cancer Vaccine Launch Pad This is the third cancer vaccine study run through NHS England's Cancer Vaccine Launch Pad (CVLP), a national programme that matches eligible patients with nearby trials. Other CVLP trials are investigating vaccines for patients with colorectal carcinoma and with melanoma. The initiative is coordinated by the University of Southampton's Clinical Trials Unit. Difficult to Treat, High Recurrence More than 11,000 new head and neck cancer cases are diagnosed each year in England. Despite improvements in care, the advanced form of the disease is difficult to treat and has high rates of recurrence, with 2-year survival rates below 50%. The investigational vaccine, known as BNT113, encodes two oncoproteins commonly found in HPV16-positive head and neck squamous cell carcinoma – the most common type, accounting for 95% of these types of cancers. The AHEAD-MERIT trial is an open-label phase II/III randomised study. It will assess BNT113 in combination with pembrolizumab, a PD-1 inhibitor, versus pembrolizumab alone as a first-line treatment for patients with unresectable, recurrent, or metastatic HPV16-positive head and neck cancers expressing PD-L1. 'Potentially Transformative' Approach Professor Peter Johnson, NHS England's national clinical director for cancer, called the vaccine 'potentially transformative' and said it offered 'renewed hope of holding the disease at bay'. Chris Curtis, who was diagnosed with HPV-related head and neck cancer in 2011 and founded the support charity The Swallows, said the vaccine could help people 'get on with their lives and move forward'. Expanding Access to Personalised Treatment The CVLP is part of a strategic partnership between NHS England, the government, and BioNTech. NHS England said it has accelerated cancer trial activity, with faster site activation and enrolment compared with standard processes. The programme aims to match thousands more cancer patients to vaccine and immunotherapy trials in the future. In April, NHS England announced that patients with advanced melanoma would be fast-tracked into the SCOPE study, a clinical trial for a new cancer vaccine. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said the CVLP was 'an important route to fast-track promising mRNA vaccine technology into clinical trials.' He added, 'Research into personalised cancer treatments is vital.'
Yahoo
6 days ago
- Business
- Yahoo
Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships
The global cancer vaccine market is experiencing robust growth driven by rising cancer cases, advancements in immunotherapy, and novel vaccine development technologies. Both preventive (e.g., HPV, HBV) and therapeutic vaccines are gaining traction, supported by increased R&D investments, especially in mRNA platforms and neoantigen vaccines. Innovations like AI and genome sequencing are enhancing personalized therapies, while FDA approvals boost confidence in clinical efficacy. With strong healthcare infrastructure in North America and Europe, and rising demand in Asia-Pacific, the market is poised for continued expansion, despite challenges like high R&D costs and complex regulations. Leading companies include Merck, Dynavax, and Moderna, with future growth focusing on personalized medicine, next-gen platforms, and oncology research funding. Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Cancer Vaccine Market - A Global and Regional Analysis: Focus on Vaccine Type, Technology Type, and Region - Analysis and Forecast, 2025-2035" report has been added to global cancer vaccine market is witnessing significant growth due to rising cancer prevalence, increasing adoption of immunotherapies, and advancements in vaccine development technologies. Cancer vaccines, both preventive and therapeutic, aim to stimulate the immune system to prevent or combat cancer. While preventive vaccines such as HPV and HBV vaccines have achieved broad adoption, therapeutic cancer vaccines are gaining traction with the development of personalized and targeted in the cancer vaccine market is supported by the growing investments in R&D, particularly in mRNA vaccine platforms and neoantigen-based vaccines, are fuelling innovation across the cancer vaccine market. Companies are leveraging AI and genome sequencing to design individualized vaccines targeting tumor-specific mutations. The FDA approvals of vaccines such as Sipuleucel-T and BCG for prostate and bladder cancer, respectively, have further validated the clinical potential of cancer increasing incidence of cancer globally, alongside unmet medical needs in oncology, is driving demand for novel vaccine approaches that can provide long-term immune memory and minimal side effects. Immunotherapy's success in other areas has also increased confidence in vaccine-based cancer treatments, spurring regulatory support and clinical trials across solid and hematologic market growth is underpinned by strong healthcare infrastructure in North America and Europe, rising awareness, and supportive reimbursement policies. The Asia-Pacific region is emerging as a high-growth area due to expanding healthcare access, government initiatives, and local manufacturing capabilities. The cancer vaccine market will continue to evolve with a strong focus on therapeutic innovations, including neoantigen-targeted and mRNA-based approaches. Advancements in precision oncology and global commitment to reducing cancer burden will shape the trajectory of the cancer vaccine market as a cornerstone of future cancer positive growth prospects, the cancer vaccine market faces challenges such as high R&D costs, complex regulatory pathways, and limited efficacy of some therapeutic vaccines. Additionally, patient-specific manufacturing and storage logistics for personalized vaccines pose scalability competitive landscape includes major players such as Merck, Dynavax Technologies and Dendreon, as well as innovative biotech firms like Moderna, BioNTech, Transgene, Imugene, and OSE Immunotherapeutics. Collaborations between pharma and biotech companies, academic institutions, and research consortia are accelerating pipeline ahead, the cancer vaccine market is projected to grow steadily, driven by the expansion of personalized medicine, next-generation vaccine platforms, and increased funding for oncology research. Integration of digital health for patient tracking and AI-assisted trial designs is expected to optimize treatment outcomes and regulatory timelines. Key Topics Covered: 1. Global Cancer Vaccine Market: Industry Analysis1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis1.3 Key Market Trends1.3.1 Impact Analysis1.4 Patent Analysis1.4.1 Patent Filing Trend (by Country)1.4.2 Patent Filing Trend (by Year)1.5 Regulatory Landscape1.6 Ongoing Clinical Trials1.7 Market Dynamics1.7.1 Overview1.7.2 Market Drivers1.7.3 Market Restraints1.7.4 Market Opportunities2. Global Cancer Vaccine Market, by Vaccine Type, $Million, 2023-20352.1 Preventive Vaccines2.1.1 Gardasil2.1.2 HEPLISAV-B2.2 Therapeutic Vaccines2.2.1 Bacillus Calmette-Guerin (BCG)2.2.2 Sipuleucel-T (Provenge)3. Global Cancer Vaccine Market, by Technology Type, $Million, 2023-20353.1 Recombinant3.2 Cell-based3.3 Others4. Global Cancer Vaccine Market, by Region, $Million, 2023-20354.1 North America4.1.1 Market Dynamics4.1.2 Market Sizing and Forecast4.1.3 North America Cancer Vaccine Market, by Country4.1.3.1 U.S.4.2 Europe4.2.1 Market Dynamics4.2.2 Market Sizing and Forecast4.2.3 Europe Cancer Vaccine Market, by Country4.2.3.1 U.K.4.2.3.2 France4.2.3.3 Germany4.2.3.4 Italy4.2.3.5 Spain4.3 Asia-Pacific4.3.1 Market Dynamics4.3.2 Market Sizing and Forecast4.3.3 Asia-Pacific Cancer Vaccine Market, by Country4.3.3.1 Japan5. Global Cancer Vaccine Market, Competitive Landscape and Company Profiles5.1 Competitive Landscape5.1.1 Mergers and Acquisitions5.1.2 Partnership, Alliances and Business Expansion5.1.3 New Offerings5.1.4 Regulatory Activities5.1.5 Funding Activities5.2 Company Profiles5.2.1 Overview5.2.2 Top Products / Product Portfolio5.2.3 Top Competitors5.2.4 Target Customers/End-Users5.2.5 Key Personnel5.2.6 Analyst View Merck & Co., Inc., Dynavax Technologies Corporation Dendreon Pharmaceuticals LLC Moderna, Inc BioNTech SE Transgene S.A. Imugene Limited Ose-Immuno Barinthus Biotherapeutics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Russia Today
03-08-2025
- Health
- Russia Today
Russian lab unveils when first patients will receive cancer vaccine
Russia's first patients could begin receiving a newly developed cancer vaccine within the next few months, Alexander Gintsburg, director of the Gamaleya Research Institute of Epidemiology and Microbiology, has announced. The breakthrough drug is a personalized, AI-assisted, mRNA-based vaccine designed to target malignant tumors using the patient's own genetic data. Speaking to RIA Novosti on Saturday, Gintsburg confirmed that the experimental phase of administering the vaccine will start 'in the coming months,' in cooperation with two leading oncology institutions – the Hertsen Research Institute and the Blokhin Cancer Center in Moscow. According to Gintsburg, the Gamaleya Center is responsible for producing the vaccine, while patient trials will be conducted by the partnering clinics. 'In accordance with the plan approved by the Health Ministry, we are preparing to begin experimental treatment using the cancer vaccine based on neoantigens in a group of melanoma patients,' Gintsburg said. He emphasized that the drug is 'entirely personalized,' created specifically for each patient using their unique tumor data, and cannot be used for anyone else. The development of the vaccine began in mid-2022 and applies messenger RNA (mRNA) technology. The treatment works by training the patient's immune system to recognize tumor-specific proteins (antigens) and destroy malignant cells throughout the body using cytotoxic lymphocytes. Due to its individualized nature, the cancer vaccine is subject to a unique regulatory framework adopted by the Russian government earlier this year. 'This is a fundamentally different process from the registration of standard drugs,' Gintsburg explained, noting that the team is working closely with health authorities to move forward under the new guidelines. The vaccine, initially designed for melanoma patients, has already shown promising results in animal trials and limited tests on human patients. Gintsburg previously stated that the entire production process – from analyzing the tumor to creating a tailored vaccine – can be completed in about a week with the help of artificial intelligence. The Gamaleya Center, which created the world's first registrede Covid-19 vaccine, Sputnik V, is also currently developing models for treating other oncological diseases, including pancreatic, kidney, and non-small-cell lung cancer – the most frequently diagnosed cancer with the highest mortality rate and one that is notoriously difficult to treat. Russia's Health Ministry estimates there are around 4 million cancer patients in the country, with roughly 625,000 new cases diagnosed annually. The cancer vaccine project could become a major milestone in Russia's public health strategy if it proves safe and effective during the upcoming trial phase. The innovation has attracted international interest, with Gintsburg confirming that several foreign medical institutions have reached out to express a desire to collaborate.
National Post
31-07-2025
- Health
- National Post
Genvira and Labskin Receive £1.2 Million ($2.0 Million) UK–Canada Collaboration Award to Advance Immunotherapies for Malignant Melanoma
Article content OTTAWA, Ontario & YORK, England — Genvira Biosciences Inc. ('Genvira'), a Canadian innovator in next-generation viral vectors, Labskin Limited ('Labskin'), a leader in 3D in vitro human skin models, and the National Research Council of Canada (NRC) are pleased to announce the launch of a collaborative project to develop novel immunotherapies for malignant melanoma. The collaboration is receiving advisory services and up to £1.2 million ($2.0 million) in funding through the Canada–UK Biomanufacturing of Biologics and Advanced Therapies program. UK participants are supported by Innovate UK, part of UK Research and Innovation (UKRI), while in Canada, support for the project is offered through the NRC Industrial Research Assistance Program (NRC IRAP) and the NRC Collaborative Science and Technology Innovation Program (NRC CSTIP). Article content Malignant melanoma continues to be a serious global health concern, with an estimated 330,000 new cases and 60,000 deaths each year. This international partnership aims to address the unmet need by developing cutting-edge cancer vaccines and optimizing targeted antigen delivery systems. Article content As part of the collaboration, Labskin will utilize its expertise in advanced disease modeling to develop a novel 3D human skin model of melanoma, enabling in vitro testing of vaccine candidates. Genvira will contribute its proprietary viral vector and gene delivery platforms, while the NRC will support the integration of mRNA technologies to engineer innovative, targeted immunotherapies tailored to melanoma. Article content Dr. Nicola Kingswell Article content , Scientific Director at Labskin Limited, stated: Article content 'We're extremely grateful to Innovate UK for supporting this exciting project. It represents a step-change in the treatment of malignant melanoma, which will benefit many patients worldwide. This partnership will not only produce and validate new immunotherapies, but also establish a framework for developing future cancer therapeutics.' Article content Dr. Jiahu Wang Article content , President of Genvira Biosciences, added: Article content 'We'd like to thank NRC IRAP for their support, and the NRC for their collaborative role. This partnership enables us to rapidly translate our viral vector technologies into clinical applications for melanoma and lays the groundwork for broader advances in cancer immunotherapy.' Article content The project brings together unique and complementary strengths in 3D tissue engineering, gene and viral therapy, mRNA technology, and advanced biomanufacturing. In addition to therapeutic development, the consortium will focus on scalable production processes, quality control assays, and robust technologies to enable rapid response to future healthcare challenges. Article content This initiative highlights the importance of international collaboration in driving innovation and accelerating the development of advanced biologics and therapies. Article content About Labskin Limited Article content Labskin Limited is a UK-based biotechnology company specializing in full-thickness human skin models for pharmaceutical, cosmetic, and clinical research. Its advanced 3D platforms offer realistic testing environments for evaluating treatments in vitro. Article content Article content
BBC News
16-06-2025
- Health
- BBC News
Birmingham cancer patient offered hope with new vaccine
Steve Haycock is one of the first people in the world to be given a cancer vaccine under a ground-breaking trial that changes the approach to the he waited for his final dose at Birmingham's Queen Elizabeth Hospital (QE), he shared with the BBC what it meant to be part of the programme, one that could bring fresh hope to patients. He also shared the irony of being married 43-year-old has been battling an aggressive form of bowel cancer, and as part of his standard treatment, has had most of his colon removed. Taking part in the trial was, then, a positive, he said. But at the same time, "it's a funny thing to process".That's because when he was selected, it was on the basis he was deemed at highest risk of his cancer returning. It's a second bite the vaccine is trying to head off. The process saw samples from his tumour sent away for genetic analysis, after which abnormal proteins produced by the cancer were identified and used to help create the vaccine, which was produced with the same mRNA technology used in several Covid boosts his immune system to look for the proteins and destroy the cancer cells associated with hope is it both mops up any cancer cells left after traditional treatment and also trains the body to recognise and destroy cancer cells that might return in the Haycock said he was only the second patient in the UK to have taken part in the the time of the vaccine's final dose, he had had almost 20. The first left him with side effects including a high temperature and shaking, he said. They eased after several hours, and faded as the treatment went last dose was a special day. Coffee, and a cake he made, was shared around his floor at the QE. The QE's principal investigator for the trial, consultant clinical oncologist Dr Victoria Kunene, watched Mr Haycock's final treatment - as she promised she would when it started a year 1.3ml was delivered slowly by the air of celebration, the doctor said it would be some time before it was known how effective the treatment had been; that's the nature of a medical trial like this."It's only by waiting you'll know if it's done the job," she said. Two years is a good indicator as to whether things are working. In five years, if patients like Mr Haycock are still cancer free, then we have a potential promising new the signs are good. This approach has already shown promising results in treating advanced skin the vaccine, Mr Haycock said, "I'd just be waiting for that moment, for it to come back"."But now I've got the security that I am part of this amazing trial."Thanks to the doctors, nurses, scientists and patients taking part in the trial, the hope is that one day, treating even the most aggressive cancers may be possible with a tiny syringe. Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram.
